Intravitreal Bevacizumab Avastin, Roche, United Kingdom for exudative maculopathies - Intravitreal bevacizumab

IVERSITA DEGLI STUDI DI UDINE0 个研究点目标入组 30 人开始时间: 2006年2月17日最近更新: 2012年3月19日

试验速览

暂无简介。

•- Patients with diffuse clinically significant diabetic macular edema CSDME ETDRS criteria either unresponsive to prior treatments laser or intravitreal triamcinolone or combined or very severe at initial presentation - Patients with nonischemic branch retinal vein occlusion BRVO or central retinal vein occlusion CRVO and severe cystoid macular edema either unresponsive to prior treatments or persisting after 6 months since initial presentation - Patients with age-related macular degeneration AMD and subfoveal choroidal neovascularization CNV either unresponsive to prior PDT or unlikely to respond to PDT large subretinal hemorrhage, large PED, large minimally classic lesion, chorioretinal anastomosis - Patients with age-related macular degeneration AMD and stage II-III retinal angiomatous proliferation RAP
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•EYE - History of any ocular surgery within the previous 6 months - Significant media opacities - Macular ischemia at fluorescein angiography MEDICAL - Chronic liver disease, clinical jaundice, and/or elevation of liver-related laboratory results 2 times the upper limit of normal - Chronic renal failure on dialysis - Stroke - Congestive heart failure or myocardial infarction - Cancer

发起方

IVERSITA DEGLI STUDI DI UDINE